1	Diagnostic accuracy of rapid antigen tests in pre-/asymptomatic close contacts of
2	individuals with a confirmed SARS-CoV-2 infection
3	
4	E Schuit PhD ^{1,2*\$} and IK Veldhuijzen PhD ^{3*} , RP Venekamp PhD ¹ , W van den Bijllaardt MD ⁴ ,
5	SD Pas PhD ^{4,5} , EB Lodder MD ⁶ , R Molenkamp PhD ⁷ , CH GeurtsvanKessel PhD ⁷ , J.Velzing
6	MSc ⁷ , RC Huisman BSc ⁷ , L Brouwer PhD ⁸ , T Boelsums MD ⁸ , GJ Sips PhD ^{3,8} , KSM
7	Benschop PhD ³ , L Hooft PhD ^{1,2} , JHHM van de Wijgert PhD ^{1,9} , S van den Hof PhD ^{3#} and
8	KGM Moons PhD ^{1,2#}
9	
10	* Dual first authorship
11	[#] Dual senior authorship
12	
13	¹ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht,
14	Utrecht University, Utrecht, The Netherlands
15	² Cochrane Netherlands, University Medical Center Utrecht, Utrecht University, Utrecht, The
16	Netherlands
17	³ Centre for Infectious Disease Control, National Institute for Public Health and the
18	Environment (RIVM), Bilthoven, The Netherlands
19	⁴ Microvida Laboratory for Medical Microbiology, Amphia Hospital, Breda, The Netherlands
20	⁵ Microvida Laboratory for Medical Microbiology. Bravis Hospital, Roosendaal, The
21	Netherlands
22	⁶ Public Health Service West-Brabant, Breda
23	⁷ Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands
24	⁸ Public Health Service Rotterdam-Rijnmond, Rotterdam

- ⁹ Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool,
- 26 Liverpool, UK
- 27
- 28 ^{\$} Corresponding author. Karel GM Moons, Julius Center for Health Sciences and Primary
- 29 Care, University Medical Center Utrecht, Utrecht University, Universiteitsweg 100, 3584 CG
- 30 Utrecht, The Netherlands. E-mail: k.g.m.moons@umcutrecht.nl.

31 Abstract

32 Background Pre-/asymptomatic close contacts of SARS-CoV-2 infected individuals were 33 tested at day 5 after contact by real-time reverse transcriptase polymerase chain reaction (RT-34 PCR). Diagnostic accuracy of antigen-detecting rapid diagnostic tests (Ag-RDT) in pre-35 /asymptomatic close contacts was up till now unknown. 36 Methods We performed a prospective cross-sectional diagnostic test accuracy study. Close 37 contacts (e.g. selected via the test-and-trace program or contact tracing app) aged ≥ 16 years 38 and asymptomatic when requesting a test, were included consecutively and tested at day 5 at 39 four Dutch public health service test sites. We evaluated two Ag-RDTs (BD VeritorTM System 40 Ag-RDT (BD), and Roche/SD Biosensor Ag-RDT (SD-B)) with RT-PCR as the reference 41 standard. Virus culture was performed in RT-PCR positive individuals to determine the viral 42 load cut-off above which 95% was culture positive, as a proxy of infectiousness. 43 **Results** Of 2,678 BD-tested individuals, 233 (8.7%) were RT-PCR positive and BD detected 44 149 (sensitivity 63.9%; 95% confidence interval 57.4%-70.1%). Out of 1,596 SD-B-tested 45 individuals, 132 (8.3%) were RT-PCR positive and SD-B detected 83 (sensitivity 62.9%; 46 54.0%-71.1%). When applying an infectiousness viral load cut-off $\geq 5.2 \log 10$ gene 47 copies/mL, the sensitivity was 90.1% (84.2%-94.4%) for BD, 86.8% (78.1% to 93.0%) for 48 SD-B overall, and 88.1% (80.5%-93.5%) for BD, 85.1% (74.3%-92.6%) for SD-B for those 49 still asymptomatic at the actual time of sampling. Specificity was >99% for both Ag-RDTs in 50 all analyses. 51 Conclusions The sensitivity for detecting SARS-CoV-2 of both Ag-RDTs in pre-

51 conclusions the sensitivity for detecting SFRS-Cov-2 of both Ag-RDFs in pre52 /asymptomatic close contacts is over 60%, increasing to over 85% after applying an
53 infectiousness viral load cut-off.

54 **Trial registration number** Not applicable. A study protocol is available upon request.

55 Introduction

56 The cornerstone of COVID-19 epidemic control has been the implementation of generic 57 infection control measures (hand hygiene, physical distancing, and staying at home when 58 symptomatic) combined with test-and-trace programs. Mathematical modelling studies have 59 shown that test-and-trace programs, in combination with generic infection control measures, 60 can successfully control SARS-CoV-2 epidemics, even when assuming that up to 40% of transmissions may occur by pre-/asymptomatic individuals 1,2 . However, they can only reduce 61 the reproductive number below 1.0 when test-and-trace delays are minimized ^{3,4}. In test-and-62 63 trace programs, contacts of infected individuals are actively traced and offered testing, initially only when symptomatic, but increasingly also when pre-/asymptomatic⁵. 64

65 In the first phase of the epidemic, testing was performed by reverse transcriptase polymerase 66 chain reaction (RT-PCR) of combined oral-nasal/nasopharyngeal swabs. The sensitivities of 67 these tests increase as the upper respiratory tract viral load increases, and reaches a high plateau on day 5 after infection ^{6,7}. While RT-PCR is considered the reference test for SARS-68 69 CoV-2, it also has disadvantages. RT-PCR testing platforms are typically only available in 70 centralized laboratories and require sample batching, thereby introducing testing delays. 71 Point-of-care SARS-CoV-2 tests became available during the global pandemic, and of these, 72 lateral flow antigen-detecting rapid diagnostic tests (Ag-RDT) are promising. They require no 73 or minimal equipment, provide a result within minutes, and can be performed in a range of 74 settings with relatively little training.

At the end of 2020, Ag-RDT had been evaluated and considered sufficient to replace RT-PCRs, notably if not only in symptomatic individuals. Diagnostic accuracies may, however, be lower in asymptomatic individuals and in samples containing lower SARS-CoV-2 viral loads ⁸. The latter is not necessarily problematic if lower viral load translates into lower subsequent expected infectiousness ⁹. The very few Ag-RDT evaluations performed in

80	asymptomatic individuals thus far had small sample sizes ¹⁰ , did not take into account whether
81	the tested individual had been exposed to an index case ¹¹ , nor was virus culture performed ¹² .
82	Therefore, we conducted this first large scale prospective diagnostic test accuracy study in
83	pre-/asymptomatic close contacts of index cases to quantify the accuracy of two Ag-RDTs for
84	detecting SARS-CoV-2 infection with RT-PCR as the reference standard.
85	
86	
87	Methods
88	Ethical review
89	The Medical Ethics Review Committee (METC) Utrecht concluded that ethics approval was
90	not required because the study is outside the scope of the Dutch Medical Research Involving
91	Human Subjects Act (protocol number: 20/750). All participants signed an informed consent
92	form prior to any study procedure.
93	
94	Study design and population
95	This prospective cross-sectional diagnostic test accuracy study was embedded within the
96	Dutch routine testing infrastructure. As of 1 December 2020, Dutch policy encourages close
97	contacts who are still pre-/asymptomatic to schedule a test on the fifth day since last exposure
98	to an index case (referred to as a 'fifth day test'). In the Netherlands, individuals are notified
99	as a close contact by the Dutch public health service test-and-trace program, and/or the Dutch
100	contact tracing mobile phone application (the 'CoronaMelder' app) and/or an individual with
101	a confirmed SARS-CoV-2 infection (index case). Participants were recruited consecutively at
102	four Dutch public health service test sites, located in the West-Brabant region
103	(Raamsdonksveer and Roosendaal) and in the city of Rotterdam (Rotterdam Ahoy and

105 these test sites were considered eligible if they were aged 16 years or older, scheduled for a 106 fifth day test, asymptomatic at the time of the test request, and willing and able to sign an 107 informed consent in Dutch language.

108

109 Inclusion procedure

Participants arrived at the test sites by car (West-Brabant) or by foot (Rotterdam). Test site personnel approached them and verbally verified study eligibility. Eligible individuals received a study flyer and a participant information letter. After signing the informed consent form, a short questionnaire on presence, type and onset of symptoms (Supplementary Material 1) was completed by participants themselves (West-Brabant) or by test site personnel (Rotterdam), while participants waited for sampling. Questionnaire data were extracted in duplicate by two independent persons.

117

118 Specimen collection, testing procedures and virus culture procedures

A detailed description of collecting, testing, including culturing, of specimens can be found in the Supplementary Material 2. Trained personnel took two combined oropharyngeal-nasal (West-Brabant) or oro-nasopharyngeal (Rotterdam) swabs from each study participant: the first for an RT-PCR test and the second for an Ag-RDT. Swabs were transported to relevant offsite and onsite laboratories, respectively.

During the study period, all study sites were using Roche COBAS6800/8800 platforms for RT-PCR testing (Supplementary Material 2), the sites in West-Brabant were using the BD VeritorTM System for Rapid Detection of SARS-CoV-2 Ag-RDT ('BD'; Becton, Dickinson and Company, Franklin Lakes, NJ, USA), and the Rotterdam sites the Roche/SD Biosensor SARS-CoV-2 Rapid Antigen Test ('SD-B'; Roche Diagnostics, Basel, Switzerland). Both Ag-RDT were applied according to manufacturer instructions with one exception: BD results

130	were determined visually instead of using a BD Veritor Plus Analyzer. Interpretation of Ag-
131	RDTs was always done prior to (thus blinded for) RT-PCR. Similarly, Ag-RDT results were
132	not available to those assessing RT-PCR results. Participants received the RT-PCR result, but
133	not the Ag-RDT result, to direct further management (such as quarantaine advice).

134

At the Erasmus MC Viroscience diagnostic laboratory, samples of participants with a positive RT-PCR test result were cultured for seven days, and, once cytopathic effects (CPE) were visible, the presence of SARS-CoV-2 was confirmed with immunofluorescent detection of SARS-CoV-2 nucleocapsid protein (Rabbit polyclonal antibody, Sino Biological inc.), Eschborn, Germany) (Supplementary Material 2).

140

141 *Outcomes and statistical analyses*

The primary outcome was the diagnostic accuracy (in terms of sensitivity, specificity, positive
and negative predictive values with their 95% confidence intervals) of each Ag-RDT, with
RT-PCR as reference standard. Since the number of individuals without RT-PCR or Ag-RDT

result was very low (n=21 (0.5%); Figure 1), a complete case analysis was performed.

146 Secondary outcomes included the diagnostic Ag-RDT accuracies stratified for a) the 147 occurrence of COVID-19-like symptoms between test request and time of sampling (yes vs. 148 no), b) the number of days between last contact and date of sampling (<5 vs. 5 vs. >5 days), c) 149 different viral load cut-offs and the viral load cut-off above which 95% of RT-PCR positives 150 had a positive culture as a proxy of infectiousness. To the latter aim, Ct values were first 151 converted into viral loads (virus gene copies/ml) using a standard curve (Supplementary 152 Material 2). The infectiousness cut-off was defined as the viral load above which 95% of RT-153 PCR positives showed in vitro infectivity in cell culture.

154	Finally, we used routine national testing data to determine whether any RT-PCR-negative
155	participants at day 5, afterwards tested positive by RT-PCR or Ag-RDT within 10 days after
156	the initial RT-PCR test, to determine whether testing pre-/asymptomatic individuals at day 5
157	since last contact with the index case, may be too early.
158	

159 Sample size considerations

Previous Ag-RDT performance studies in symptomatic individuals found sensitivities of around 85% ^{9,13-15}. We based our sample size calculation on an expected sensitivity of 80%, with a margin of error of 7%, type I error of 5% and power of 90%. Hence, we aimed for 140 positive RT-PCR tests for each Ag-RDT vs. RT-PCR test comparison. We anticipated a SARS-CoV-2 prevalence (based on RT-PCR) in our target population of 10%, and closely monitored RT-PCR test positivity proportion over time to prolong recruitment if needed.

166

167 Results

Between 14 December 2020 and 6 February 2021, 5,191 individuals were considered eligible for participation of whom 4,296 participated (Figure 1). Both RT-PCR and Ag-RDT results were available for 2,678 (99.5%) and 1,596 (99.5%) participants in the BD and SD-B group, respectively. The BD and SD-B groups were similar: respectively the mean ages (standard deviation (SD); in years) were 45.9 (SD 17.6) and 40.7 (SD 16.4), 51.3% and 47.3% were female, and 8.6% and 10.1% had developed symptoms at the time of sampling (Table 1).

In the BD group, 233 (8.7%) had an RT-PCR-confirmed SARS-CoV-2 infection; 149 were detected by the BD Ag-RDT resulting in an overall sensitivity of 63.9% (95% CI 57.4% to 70.1%) (Table 1). In the SD-B group, 132 (8.3%) had an RT-PCR-confirmed SARS-CoV-2

infection; 83 were detected by the SD-B Ag-RDT resulting in an overall sensitivity of 62.9%

179 (95% CI 54.0% to 71.1%).

In individuals who had developed symptoms between the test request and the time of sampling, the sensitivity was 84.2% (95% CI 68.7% to 94.0%) for BD (N=219) and 73.3% (95% CI 54.1% to 87.7%) for SD-B (N=158). Additional stratified diagnostic accuracy parameters are shown in Table 1. Two by two tables of all primary and secondary analyses are presented in Tables S2 and S3.

185

186 Figure 2 shows the distribution of viral loads in individuals with a positive RT-PCR test 187 result, stratified by a combination of the SD-B Ag-RDT result and the ability to culture virus. 188 Above a viral load of 5.2 log10 E-gene copies/mL, 95% of RT-PCR positive individuals 189 showed a positive virus culture. Using that viral load as a cut-off for infectiousness, the 190 sensitivity was 90.1% (95% CI 84.2% to 94.4%) for BD and 86.8% (95% CI 78.1 % to 93.0 191 %) for SD-B, respectively. Figure 3 shows diagnostic accuracy parameters stratified by 192 different viral load cut-offs. The sensitivity of both Ag-RDTs at the infectious viral load cut-193 off in persons without symptoms at the time of sampling was 88.1% (95% CI 80.5% to 194 93.5%) for BD and 85.1% (74.3% to 92.6%). Other diagnostic accuracy parameters for this 195 group are presented in more detail in Table S4, and at varying viral load cut-offs in 196 Supplementary Figure 2.

197

Finally, routine national testing follow-up information was available for 89% of all included study participants. A total of 31 (1.5%) and 26 (2.0%) individuals had a positive RT-PCR test result within 10 days after an initial negative RT-PCR test result in the BD and SD-B group, respectively.

203 **Discussion**

204 To our knowledge, this is the largest study thus far to specifically assess the diagnostic test 205 accuracy of Ag-RDTs in pre-/asymptomatic close contacts. Our study shows that two Ag-206 RDTs, that are routinely used for symptomatic individuals, have around 63% sensitivity for 207 detecting SARS-CoV-2 in pre-/asymptomatic close contacts. However, both Ag-RDTs 208 particularly appeared to show a negative result – while the corresponding RT-PCR test was 209 positive – in those with a lower viral load ranges. At viral loads above 5.2 log10 E gene 210 copies/mL (the assumed viral load cut-off for infectiousness based on viral culture results), 211 both Ag-RDTs showed sensitivities over 85%, i.e. above the WHO sensitivity criteria defined 212 for Ag-RDTs in symptomatic individuals. Specificity was >99% for both Ag-RDTs in all 213 analyses. About 2% of close contacts who initially tested RT-PCR negative at day 5, 214 developed symptoms and subsequently tested positive after day 5. This rather low percentage 215 indicates that testing close contacts that are still asymptomatic at day 5, is not too early.

The prevalence of SARS-CoV-2 infections among all adults, both symptomatic and pre-/asymptomatic, tested as part of contact tracing in all the public health service testing sites in the study period, was 18% ¹⁶. This percentage is comparable to the prevalence among symptomatic close contacts in our study population. Although the prevalence in pre-/asymptomatic close contacts is expectedly lower, it is considerably higher than the prevalence of 0.8%-1% (at the time of the study period) as estimated in the general population of the Netherlands ¹⁶, and in other countries ^{17,18}.

Only about 2% of close contacts who initially tested RT-PCR negative at day 5 after the close contact developed symptoms and subsequently tested positive, i.e. infections missed by RT-PCR on day 5 after exposure to an index case. These proportions of 'missed' infections are expected to increase when using an Ag-RDT instead of RT-PCR. This underlines the

importance of immediate self-isolation and repeat testing when symptoms develop after anegative day 5 Ag-RDT.

The extent to which the lower sensitivity of Ag-RDTs compared to RT-PCR outweighs the positive effects of simplified logistics, reduced delays, and the potential for self-testing, is currently unknown. We will monitor this utiziling national test-and-trace information. Modeling studies will also help to further address this question in the future.

We were also able to minimize missing values and measurement bias by taking samples for the Ag-RDT and RT-PCR from each participant at the same time, using the same Ag-RDT and RT-PCR reference test for all participants, and having all (index and reference) tests performed by trained personnel who were blinded to the result of the other test.

237 Our study also has some potential limitations. First, although we aimed to sample pre-238 /asymptomatic individuals at five days after exposure to an index case, 12% was sampled 239 before the fifth day since last contact. It is known that the accuracy of the RT-PCR reference test is not yet optimal before the fifth day after contact with an index case ⁶. Interestingly 240 241 though, our stratified analysis indicated that the RT-PCR positivity fraction was actually 242 higher in close contacts who were sampled before the fifth day since last contact. We 243 hypothesize that some of these individuals have had prolonged contact with the index case, 244 for example because they live in the same household. Close contacts living in the same 245 household on average test more often positive compared to non-household close contacts 246 $(20\% \text{ vs. } 10\%)^{16}$. This would also explain why these close contacts reported to have contact 247 with the index case less than 5 days ago, as the last contact with an infected household 248 member could be the same day of testing. A second limitation is that virus culture was only 249 available in one of the two central laboratories. Hence, the assumed infectiousness viral load 250 cut-off was extrapolated to the second laboratory. Reassuringly, the RT-PCR calibration 251 curves of both laboratories indicated that Ct values corresponded to similar viral loads in both

laboratories. A correlation between infectivity in culture and viral load of the specimen as well as negative associations between lower viral loads and secondary attack rates have been established ¹⁹⁻²². Some uncertainty remains as the exact upper respiratory tract viral load cutoff below which transmissions no longer take place is yet unknown, and due to high variability in methodologies and results between laboratories and studies ^{21,22}.

257 The Dutch Outbreak Management Team (OMT) that provides guidance to the Ministry of 258 Health, Welfare and Sport on policy regarding COVID-19, advised, based on the results of 259 this study, that pre-/asymptomatic close contacts of individuals with a confirmed SARS-CoV-260 2 infection can be tested for SARS-CoV-2 using an Ag-RDT. As a result the Dutch policy 261 now allows testing of close contacts using Ag-RDTs from day 5 onwards, even when they 262 have not (yet) developed symptoms. Accordingly, positive test results are known and 263 communicated earlier such that the use of Ag-RDTs in pre-/asymptomatic close contacts has 264 the potential to help prevent onward SARS-CoV-2 transmission.

266 **References**

267

- 268 1. Ferrari A, Santus E, Cirillo D, et al. Simulating SARS-CoV-2 epidemics by region-
- specific variables and modeling contact tracing app containment. NPJ Digit Med 2021;4:9.
- 270 2. Kucharski AJ, Klepac P, Conlan AJK, et al. Effectiveness of isolation, testing, contact
- 271 tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different

settings: a mathematical modelling study. Lancet Infect Dis 2020;20:1151-60.

- 3. Ferretti L, Wymant C, Kendall M, et al. Quantifying SARS-CoV-2 transmission
 suggests epidemic control with digital contact tracing. Science 2020;368.
- 4. Kretzschmar MER, G.; Bootsma, M.; van Boven, M.; van de Wijgert, J.; Bonten, M.

Time is of the essence: impact of delays on effectiveness of contact tracing for COVID-19, amodelling study. medRxiv 2020.

5. COVID-19 Test-and-tracing protocol. 2021. at <u>https://lci.rivm.nl/COVID-19-bco</u>.)

Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in FalseNegative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2
Tests by Time Since Exposure. Ann Intern Med 2020;173:262-7.

282 7. Mallett S, Allen AJ, Graziadio S, et al. At what times during infection is SARS-CoV-2

detectable and no longer detectable using RT-PCR-based tests? A systematic review of
individual participant data. BMC Med 2020;18:346.

- 8. Boehme C, Hannay E, Sampath R. SARS-CoV-2 testing for public health use: core
 principles and considerations for defined use settings. Lancet Glob Health 2021;9:e247-e9.
- 287 9. van Beek JI, Z.; Boelsums, T.; Fanoy, E.; Gotz, H.; Molenkamp, R.; van Kampen, J.;
- 288 GeurtsvanKessel, C.; van der Eijk, A.; van de Vijver, D.; Koopmans, M. From more testing to
- smart testing: data-guided SARS-CoV-2 testing choices medRxiv 2020.

- 291 Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses -
- 292 Wisconsin, September-October 2020. MMWR Morb Mortal Wkly Rep 2021;69:1642-7.
- 293 11. Winkel BMFS, E.; Gremmels, H.; Debast, S.B.; Schuurman, R.; Wensing, A.M.J.;
- 294 Bonten, M.J.M.; Goedhart, E.; Hofstra, M.; Antigen Rapid Test Validation Group. Screening
- 295 for SARS-CoV-2 infection in asymptomatic individuals using the Panbio[™] COVID-19
- 296 Antigen Rapid Test (Abbott) compared to RT-qPCR. medRxiv 2020.
- 297 12. Stohr JJJMZ, V.F.; Goderski, G.; Meijer, A.; Nagel-Imming, C.R.S.; Kluytmans-van
- den Bergh, M.F.Q.; Pas, S.D.; van den Oetelaar, F.; Hellwich, M.; Gan, K.H.; Rietveld, A.;
- 299 Verweij, J.J.; Murk, J.L.; van den Bijllaardt, W.; Kluytmans, J.A.J.W. Self-testing for the
- detection of SARS-CoV-2 infection with rapid antigen tests. medRxiv 2021.
- 301 13. RIVM Centrum Infectieziektebestrijding. Status validatie SARS-CoV-2 antigeen
 302 sneltesten, 10 Mar 20212021.
- 303 14. Van der Moeren NZ, V.F.; Lodder, E.B.; van den Bijllaardt, W.; van Esch, H.R.J.M.;
- 304 Stohr, J.J.J.M.; Pot, J.; Welschen, I.; van Mechelen, P.M.F.; Pas, S.D.; Kluytmans, J.A.J.W.;.
- 305 Performance evaluation of a SARS-CoV-2 Rapid antigen test: test performance in the
- 306 community in The Netherlands. medRxiv 2020.
- 307 15. Igloi ZV, J.; van Beek, J.; van de Vijver, D.; Aron, G.; Ensing, R.; Benschop, K.; Han,
- 308 W.; Boelsums, T.; Koopmans, M.; Geurtsvankessel, C.; Molenkamp, R. Clinical evaluation of
- 309 the Roche/SD Biosensor rapid antigen test with symptomatic, nonhospitalized patients in a
- 310 municipal health service drive-through testing site. medRxiv 2020.
- 311 16. weekly COVID-19 epidemiological situation reports. 2021. at
- 312 https://www.rivm.nl/coronavirus-covid-19/actueel/wekelijkse-update-epidemiologische-
- 313 <u>situatie-covid-19-in-nederland.</u>)

- 314 17. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the
- 315 Icelandic Population. N Engl J Med 2020;382:2302-15.
- 316 18. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-CoV-2 in
- 317 Women Admitted for Delivery. N Engl J Med 2020;382:2163-4.
- 318 19. Deeks JJ, Raffle AE. Lateral flow tests cannot rule out SARS-CoV-2 infection. BMJ
- 319 2020;371:m4787.
- 320 20. Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for COVID-19
- 321 infectious potential assessment a systematic review. Clin Infect Dis 2020.
- 322 21. Lee LYWR, S.; Pang, M.; Charlett, A.; Anderson, C.; Hughes, G.J.; Barnard, M.;
- 323 Peto, L.; Vipond, R.; Sienkiewicz, A.; Hopkins, S.; Bell, J.; Crook, D.W.; Gent, N.; Walker,
- 324 A.S.; Eyre, D.W.; Peto, T.E.A. An observational study of SARS-CoV-2 infectivity by viral
- load and demographic factors and the utility lateral flow devices to prevent transmission.2021.
- 327 22. Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282
- 328 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis 2021.

330 Tables

331

332 Table 1 Diagnostic accuracy parameters of both Ag-RDTs

Analysis		#	Preva-	Sensitivity [%]	Specificity [%]	Positive	Negative		
			lence*	(95% CI)	(95% CI)	Predictive	Predictive		
						Value [%]	Value [%]		
						(95% CI)	(95% CI)		
RD Varitor TM Sust	om for	Ranid Da	tection of	SARS-CoV-2 Ag			· · ·		
BD veruor System for Kapid Detection of SAKS-CoV-2 Ag-KDT ('BD')									
<u>Primary analysis</u>		2678	8.7%	63.9	99.6	94.3	96.7		
				(57.4 to 70.1)	(99.3 to 99.8)	(89.5 to 97.4)	(95.9 to 97.3)		
Secondary (stratified) analysis									
Infectiousness		2677 ^{\$}	5.7%	90.1	99.2	87.3	99.4		
viral load cut-off!				(84.2 to 94.4)	(98.8 to 99.5)	(81.0 to 92.0)	(99.0 to 99.7)		
Symptoms at	Yes	219	17.4%	84.2	99.4	97.0	96.8		
sampling [#]				(68.7 to 94.0)	(97.0 to 100)	(84.2 to 99.9)	(93.1 to 98.8)		
	No	2317	7.7%	58.7	99.6	92.9	96.6		
				(51.1 to 66.0)	(99.3 to 99.8)	(86.5 to 96.9)	(95.8 to 97.4)		
Interval between	< 5	379	14.8%	69.6	99.7	97.5	95.0		
sampling and last				(55.9 to 81.2)	(98.3 to 100)	(86.8 to 99.9)	(92.1 to 97.1)		
contact with	5	1303	6.5%	62.4	99.9	98.1	97.4		
index case				(51.2 to 72.6)	(99.5 to 100)	(90.1 to 100)	(96.4 to 98.2)		
[days] [@]	> 5	511	9.0%	56.5	99.1	86.7	95.8		
				(41.1 to 71.1)	(97.8 to 99.8)	(69.3 to 96.2)	(93.7 to 97.4)		
Roche/SD Biosensor SARS-CoV-2 Rapid Antigen Test ('SD-B')									
Primary analysis		1596	8.3%	62.9	99.5	91.2	96.7		
				(54.0 to 71.1)	(98.9 to 99.8)	(83.4 to 96.1)	(95.7 to 97.6)		
Secondary (stratified) analysis									
Infectiousness		1596	5.7%	86.8	99.2	86.8	99.2		
viral load cut-off				(78.1 to 93.0)	(98.6 to 99.6)	(78.1 to 93.0)	(98.6 to 99.6)		

Symptoms at	Yes	158	19.0%	73.3	98.4	91.7	94.0
sampling [#]				(54.1 to 87.7)	(94.5 to 99.8)	(73.0 to 99.0)	(88.6 to 97.4)
	No	1414	7.1%	59.4	99.5	90.9	97.0
				(49.2 to 69.1)	(99.0 to 99.8)	(81.3 to 96.6)	(95.9 to 97.8)
Interval between	< 5	153	13.1%	75.0	99.2	93.8	96.4
sampling and last				(50.9 to 91.3)	(95.9 to 100)	(69.8 to 99.8)	(91.7 to 98.8)
contact with	5	1095	7.8%	61.2	99.5	91.2	96.8
index case [days]				(50.0 to 71.6)	(98.9 to 99.8)	(80.7 to 97.1)	(95.6 to 97.8)
@	> 5	205	6.3%	69.2	99.5	90.0	97.9
				(38.6 to 90.9)	(97.1 to 100)	(55.5 to 99.7)	(94.8 to 99.4)
1			1	1	1	1	

333 CI = confidence interval; N/A = not applicable.

334 * SARS-CoV-2 infection based on RT-PCR test result

[#]Symptoms were not available from 142 individuals in the BD group and 24 in the SD-B group

336 [!] The viral load cut-off for infectiousness, defined as the viral load above which 95% of RT-PCR positives had a

337 positive viral culture, was 5.2 log10 E gene copies/mL.

338 ^{\$} Viral load was unavailable for one BD-tested individual with a positive RT-PCR test result

[@] The interval between the moment of sampling and the last contact with an infected individual was not available

340 for 488 individuals in the BD group and 143 individuals in the SD-B group, mainly because this question was

341 added to the questionnaire later in study. Initially, a 3-item questionnaire was used. Questions 1 and 2 in the 5-

342 item questionnaire (see Supplementary Material 1) were added after the first week of the study. In addition, do

343 note that the time interval between the last contact and the time of sampling is not the same as the time between

the test request and the time of sampling.

346 **Figure legends**

Figure 1 Flow of study participants. BD = BD VeritorTM System for Rapid Detection of
SARS-CoV-2 Ag-RDT ('BD'), SD-B = Roche/SD Biosensor SARS-CoV-2 Rapid Antigen
Test.

350 Figure 2 Distribution of viral loads of individuals with a positive RT-PCR test result, 351 stratified by a combination of the Roche/SD Biosensor SARS-CoV-2 Rapid Antigen Test 352 result (Ag-RDT+/-) and the ability to culture (culture +/-), with Ag-RDT+ and Ag-RDT-353 corresponding to a positive and negative Ag-RDT result, and culture+ and culture- indicating 354 whether it was possible to culture virus or not. 355 Figure 3 Diagnostic accuracy parameters of both Ag-RDTs for different definitions of RT-356 PCR test positivity based on viral load cut-offs, where a positive RT-PCR test with a viral 357 load below the viral load cut-off threshold is considered a negative RT-PCR test result. Points 358 highlighted in red indicate a viral load cut-off of 5.2 log10 E gene copies/mL, which was 359 considered the viral load cut-off for infectiousness as determined by viral culture. BD = BD360 VeritorTM System for Rapid Detection of SARS-CoV-2 Ag-RDT; SD-B = Roche/SD 361 Biosensor SARS-CoV-2 Rapid Antigen Test; PPV = positive predictive value; NPV =

362 negative predictive value.

363 Acknowledgements

We would like to acknowledge all participants, study personnel at the local public health service test sites, personnel at the participating labs, and study personnel at the RIVM that helped process the questionnaires, design and distribute the study forms. A special thanks goes to Esther Stiefelhagen, Roel Ensing, and Wendy Mouthaan for their efforts in the logistics towards and at the local test sites. Written permission was obtained from all three to include their names in this Acknowledgment section. ES, RE, and WH did not receive any compensation for their contributions.

371

372 Author contributions

KGMM and JHHMvdW initiated the study. ES, IKV, RPV, WvdB, EL, RM, GJS, KB, LH,
JHHMvdW, SvdH, and KGMM designed the study. IKV coordinated the study. WvdB, SDP,
RM, JV, and RCH were responsible for lab analyses and data processing. CHGvK performed
virus culture. ES performed the statistical analysis in close collaboration with IKV and
KGMM. ES, IKV, RPV, SvdH, and KGMM drafted the first version of the manuscript. All
authors critically read the manuscript and provided feedback. All authors approved the
submission of the current version of the manuscript.

380

381 **Competing interest declaration**

382 None to be disclosed.

383

384 Funding

385 The study was funded by the Dutch Ministry of Health, Welfare and Sport. The funder had no

role in the design, conduct, data-analysis or report of the study.

388 Additional information (containing supplementary information line (if any) and

- 389 corresponding author line).
- 390 The study protocol is available upon request by contacting Karel Moons at
- 391 k.g.m.moons@umcutrecht.nl.







